Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence
This study ended early.
In BostonResearchers compared JNJ-31001074 and placebo, tracking side effects to assess safety in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including IrvineA Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder
Read the official source — NCT00326391A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day.
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers studied Paliperidone Palmitate, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BaodingResearchers compared ABT-089, atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockResearchers compared JNJ-42165279 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
This study has finished and is no longer accepting participants.
Multiple locations, including La JollaA Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder
This study ended early.
Multiple locations, including ArcadiaA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects
This study was withdrawn before enrollment.
Location not clearly listedOpen-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedAn Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosThis study evaluated the safety of risperidone-SABER for people with schizophrenia.
This study has finished and is no longer accepting participants.
In GlendaleResearchers studied ABT-089, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including MesaWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.